Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 259.19M P/E - EPS this Y -85.40% Ern Qtrly Grth -
Income -106.79M Forward P/E -1.50 EPS next Y 1.20% 50D Avg Chg -12.00%
Sales 153.73M PEG 0.09 EPS past 5Y - 200D Avg Chg -28.00%
Dividend N/A Price/Book 1.39 EPS next 5Y -12.88% 52W High Chg -51.00%
Recommedations 1.80 Quick Ratio 4.39 Shares Outstanding 76.92M 52W Low Chg 5.00%
Insider Own 0.97% ROA -12.72% Shares Float 48.60M Beta 0.98
Inst Own 86.23% ROE -58.25% Shares Shorted/Prior 2.41M/2.41M Price 4.29
Gross Margin -17.36% Profit Margin -69.47% Avg. Volume 473,401 Target Price 12.89
Oper. Margin 37.95% Earnings Date May 13 Volume 258,401 Change -3.60%
About Sutro Biopharma, Inc.

Sutro Biopharma, Inc. operates as a clinical-stage oncology company. The company develops site-specific and novel-format antibody drug conjugates (ADCs) that enables its proprietary integrated cell-free protein synthesis platform, XpressCF and XpressCF+. Its product candidates include STRO-002, an ADC directed against folate receptor-alpha, which is in Phase II/III clinical trials for patients with ovarian and endometrial cancers; VAX-24 and Vax-31 pneumococcal conjugate vaccine candidates that is in Phase II/III clinical trials for the treatment of invasive pneumococcal disease; and MK-1484, a distinct cytokine derivative molecule that is in Phase I clinical study for the treatment of cancer. The company's pre-clinical product candidates include STRO-003, an ADC directed against an anti-receptor tyrosine kinase-like orphan receptor 1 (ROR1) for the treatment of solid tumors and hematological cancers; and STRO-004, a tissue factor (TF) targeting ADC for the treatment of TF-expressing solid tumors, including cervical, lung, and breast cancer. Sutro Biopharma, Inc. has collaboration and license agreements with Merck Sharp & Dohme Corporation to develop research programs focusing on cytokine derivatives for cancer and autoimmune disorders; Vaxcyte to discover and develop vaccine candidates for the treatment or prophylaxis of infectious diseases; Tasly Biopharmaceuticals Co., Ltd. to develop and commercialize STRO-002 in Greater China; EMD Serono to develop ADCs for multiple cancer targets; and Astellas Pharma Inc. to develop immunostimulatory ADC. The company was formerly known as Fundamental Applied Biology, Inc. Sutro Biopharma, Inc. was incorporated in 2003 and is headquartered in South San Francisco, California.

Sutro Biopharma, Inc. News
04/02/24 Sutro Biopharma, Inc. (NASDAQ:STRO) Analysts Just Cut Their EPS Forecasts Substantially
04/02/24 Sutro Biopharma Announces Pricing of $75 Million Underwritten Offering
03/26/24 Sutro Biopharma Inc (STRO) Earnings: A Mixed Bag Amidst Strategic Advances
05:30 PM Sutro Biopharma, Inc. (STRO) Q4 Earnings and Revenues Surpass Estimates
03:30 PM Sutro Biopharma Reports Full Year 2023 Financial Results, Business Highlights and Select Anticipated Milestones
03/21/24 Here's Why Sutro Biopharma (STRO) Is a Great 'Buy the Bottom' Stock Now
02/28/24 Sutro Biopharma, Inc. (STRO) Surges 9.5%: Is This an Indication of Further Gains?
02/06/24 Sutro Biopharma to Participate in Upcoming Investor Conferences
01/04/24 Sutro Biopharma Highlights Potential Multi-Cancer Opportunity for Luvelta, a FolRα-targeting ADC
12/18/23 Sutro Biopharma, Inc.'s (NASDAQ:STRO) Share Price Boosted 48% But Its Business Prospects Need A Lift Too
12/14/23 Sutro Biopharma to Host Investor Webcast Highlighting Potential Multi-Cancer Opportunity for Luvelta, a FolRα-targeted ADC, on January 4, 2024
12/11/23 Sutro Biopharma Announces New Positive Data from the Compassionate Use of Luveltamab Tazevibulin (luvelta) in Pediatric Patients with Relapsed/Refractory CBF/GLIS Presented at ASH 2023
12/04/23 Sutro Biopharma to Participate in the JMP Securities Hematology and Oncology Summit
11/27/23 Vaxcyte Exercises Option and Enters into Manufacturing Rights Agreement with Sutro Biopharma to Obtain Control Over Manufacturing and Development of Cell-Free Extract for its Vaccine Candidates
11/21/23 Sutro Biopharma Promotes Jane Chung to President and Chief Operating Officer
11/13/23 Sutro Biopharma Inc (STRO) Reports Q3 2023 Financial Results and Business Updates
11/13/23 Sutro Biopharma Reports Third Quarter 2023 Financial Results, Business Highlights and Select Anticipated Milestones
11/13/23 Why Sutro Biopharma (STRO) Might Surprise This Earnings Season
11/04/23 Sutro Biopharma (NASDAQ:STRO) shareholders are up 11% this past week, but still in the red over the last three years
10/22/23 Sutro Biopharma Announces Presentation of Data for Luveltamab Tazevibulin (luvelta) from the Phase 1 Dose-Expansion Study in Endometrial Cancers at ESMO 2023
STRO Chatroom

User Image ViractaTrader77 Posted - 1 hour ago

Someone at IB shorted 600.000 yesterday. This is ridiculous. Ispen and Steve Cohen just loaded at $5.18 and selling beneath cash and company is almost a clone of immunogen that was just purchased for $10 billion. $STRO (there will be a monster short squeeze here soon- I am moving all my stock into a cash account) good luck finding borrow!!!!

User Image TXcountry Posted - 11 hours ago

$STRO need these catalyst to ignite cuz trading below cash is downright hurtful

User Image Trade_and_Profit Posted - 15 hours ago

$STRO gap filled time for news and run this sucker to the moon

User Image NotOfTheBody Posted - 16 hours ago

$STRO A Fargo woodchipper day here.

User Image Trade_and_Profit Posted - 16 hours ago

$AUPH dumped some of this shit to try another pile of @ $STRO

User Image Trade_and_Profit Posted - 16 hours ago

$STRO Started a position here at $3.45

User Image sudser71 Posted - 20 hours ago

$STRO more naked shorting nonsense

User Image astroflyery1 Posted - 1 day ago

$HRTX $MREO $XERS $STRO $SPY Old investment almanacs posit that if the first five trading days of the S&P500's new year are net positive or negative, it predicts a gain or loss for the full 12 months. Hocus pocus or not, the 'five-day rule' has proven correct for five years running - despite unforeseen curve balls

User Image Dtwod7474 Posted - 1 day ago

$VINC come one over. The time is now. $STRO Make some wealth on the return! $PYXS $SLS . Value can only be held down for so long. Accumulation has happened and there are buyers!

User Image RallyRaider Posted - 1 day ago

$STRO lets see another green bar and ill try some

User Image astroflyery1 Posted - 1 day ago

$STRO Analyst Coverage:

User Image ViractaTrader77 Posted - 1 day ago

$STRO Takeover target imo $13-24 a share

User Image Jizzle14 Posted - 2 days ago

$STRO I'm in baby

User Image astroflyery1 Posted - 2 days ago

$STRO It’s clear as it’s weird….this stock is underperforming like a crazy deer.

User Image ViractaTrader77 Posted - 2 days ago

Shake and Bake $STRO $VINC

User Image astroflyery1 Posted - 3 days ago

$HRTX $STRO $APLT $MREO $SPY It's been a highly volatile week with stocks sinking on a number of news. Be it geopolitical headwinds or high inflation numbers. In the upcoming week we will see Big Tech reporting their earnings and it appears that the expectations are that they're really going to deliver again. This could give a healthy upside movement on global markets. I remain bullish.

User Image ViractaTrader77 Posted - 4 days ago

$STRO 1 major buyer IMO still lurking to grab a company like Sutro https://www.fiercepharma.com/pharma/inside-abbvies-10b-immunogen-buyout-and-bidding-war-it-won

User Image ViractaTrader77 Posted - 4 days ago

Flipper shelf funds must be out by now. That’s what drove it down plus interest rates and market. But this management team was smart they have tons of cash with Point72 and Ispen Pharma They $STRO has the same partnering business model that Immunogen had in antibody drug conjugates and same lead asset that got them acquired for $10 billion. There were 3+ big pharma players looking to acquire Immunogen and Abbvie won. I think this will get acquired for $13-24 a share this summer. $IMGN and same lead asset as Profound Bio. This is a perfect hedged opportunity (turnkey) for a big pharma to buy to grab the asset, cash and partnerships in the hottest niche in biotech. $VKTX

User Image BlndSqurrl Posted - 5 days ago

$STRO 1st buy today $3.64 - 86% tutes, 300+ employees, six ongoing registrational trials 2nd qtr - Solid science- "Mikey likes it" (*complete collapse cannot be cancelled*. . word)

User Image sudser71 Posted - 5 days ago

$STRO algo next stop $3.52

User Image NotOfTheBody Posted - 5 days ago

$STRO The LABU ETF is also getting obliterated, now down $91 bucks since its closing high only 7-weeks ago on 2/27. This ETF and the XBI bio-ETF are well into oversold territory on the RSI 14 and RSI 9, as well as the Willams %R (14). STRO and all the bio's I own, IOVA, SWTX and CHRS all in or a stone's throw away from oversold territory too. The market indices are also a stone's throw away from entering oversold territory. VIX is now in overbought territory. Not sure there is that much room left for these to tank much further...at least not until there is a big relief rally for a while in the sector. I realize the charts look ugly, but there comes a point when things are overdone and oversold. This smells like the bottom innings here and close to capitulation imo...barring any more Mid East BS.

User Image sudser71 Posted - 5 days ago

$STRO it’s naked shorts. Cohen is shorting post financing, algo will drive it down until he’s got his position.

User Image ViractaTrader77 Posted - 5 days ago

Looks like war over. Maybe market will pop back. $VINC $STRO

User Image astroflyery1 Posted - 6 days ago

$STRO And so it begins again

User Image Mastermind94 Posted - 6 days ago

$STRO I’ve been watching this for quite sometime now, I’m waiting on dry powder to settle by Monday, I hope it doesn’t take off

User Image astroflyery1 Posted - 6 days ago

$STRO We have significant catalyst ahead of us:

User Image TrustButVerifi Posted - 6 days ago

$STRO hand-job on the price when retail is scared chetless! I ve No dry powder otherwise I would add every chance I get. 10-20 bagger. I got plenty of time!

User Image BlackStallion Posted - 6 days ago

$STRO

User Image astroflyery1 Posted - 6 days ago

$STRO I think in two weeks we should be again over $4.50

User Image astroflyery1 Posted - 6 days ago

$STRO I bought again but only 1030 Shares

Analyst Ratings
Piper Sandler Overweight Apr 3, 24
Oppenheimer Outperform Apr 3, 24
Truist Securities Buy Apr 3, 24
JMP Securities Market Outperform Apr 3, 24
Oppenheimer Outperform Mar 28, 24
Oppenheimer Outperform Mar 27, 24
Wedbush Outperform Mar 26, 24
JMP Securities Market Outperform Mar 26, 24
HC Wainwright & Co. Buy Mar 26, 24
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
NEWELL WILLIAM J CEO CEO Mar 14 Buy 7.7508 10,000 77,508 116,525 03/15/22
Petree Daniel H Director Director Feb 08 Option 5.33 14,277 76,096 22,265 02/09/22